Paper 81 - PSYCHOMETRIC PROPERTIES AND MEANINGFUL CHANGE THRESHOLDS (MCT) OF THE GOUNDER/DESMOID TUMOR RESEARCH FOUNDATION DESMOID SYMPTOM/IMPACT SCALE (GODDESS) AS ASSESSED IN THE PHASE 3 DEFI TRIAL

Author(s)

• 

  Mrinal M. Gounder, MD

  Associate Attending Physician
  Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center
  New York, New York, United States

  Slides PDF

Co-Author(s)

• TA

  Thomas Atkinson, PhD

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• TB

  Timothy Bell, MHA

  SpringWorks Therapeutics
  Stamford, Connecticut, United States
• CD

  Christina Daskalopoulou, PhD

  IQVIA
  Athens, Attiki, Greece
• PG

  Pip Griffiths, PhD

  IQVIA
  Paris, Ile-de-France, France
• MM

  Moriah Martindale (she/her/hers)

  Clinical Research Associate
  Memorial Sloan Kettering Cancer Center
  Buffalo, New York, United States
• AL

  Allison Lim, PharmD

  SpringWorks Therapeutics
  Stamford, Connecticut, United States